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Abstract
Skeletal muscle constitutes the major site of glucose uptake leading to increased removal of glucose from the circulation in
response to insulin. Type 2 diabetes and obesity are often associated with insulin resistance that can be counteracted by
exercise or the use of drugs increasing the relative proportion of oxidative fibers. RIP140 is a transcriptional coregulator with
a central role in metabolic tissues and we tested the effect of modulating its level of expression on muscle glucose and lipid
metabolism in two mice models. Here, we show that although RIP140 protein is expressed at the same level in both
oxidative and glycolytic muscles, it inhibits both fatty acid and glucose utilization in a fiber-type dependent manner. In
RIP140-null mice, fatty acid utilization increases in the extensor digitorum longus and this is associated with elevated
expression of genes implicated in fatty acid binding and transport. In the RIP140-null soleus, depletion of RIP140 leads to
increased GLUT4 trafficking and glucose uptake with no change in Akt activity. AMPK phosphorylation/activity is inhibited in
the soleus of RIP140 transgenic mice and increased in RIP140-null soleus. This is associated with increased UCP1 expression
and mitochondrial uncoupling revealing the existence of a signaling pathway controlling insulin-independent glucose
uptake in the soleus of RIP140-null mice. In conclusion, our findings reinforce the participation of RIP140 in the maintenance
of energy homeostasis by acting as an inhibitor of energy production and particularly point to RIP140 as a promising
therapeutic target in the treatment of insulin resistance.
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Introduction
Skeletal muscle constitutes the major site of glucose uptake
leading to increased removal of glucose from the circulation in
response to insulin. Insulin resistance is a key feature of type 2
diabetes and obesity where it is often associated with accumulation
of intramyocellular lipids and decreased oxidative capacities in
skeletal muscle. Skeletal muscles required for sustained contractile
activity such as the soleus contain mainly ‘‘slow twitch’’ oxidative
fibers, rich in mitochondria, while those involved in rapid, shorter
bursts of activity such as the gastrocnemius and extensor digitorum
longus (EDL) contain more ‘‘fast twitch’’ fibers rich in glycolytic
enzymes for anaerobic metabolism [1]. Slow fibers tend to express
type I myosin heavy chains (MyHC) while fast fibers express IIa,
IIb and IIx isoforms [1–3]. Fiber type composition can be
modulated by different factors such as exercise, aging, and
hormonal changes [4], [5]. Endurance training leads to an
increase in the proportion of type I fibers while resistance training
promotes increased type II fibers. Although it has been shown that
increasing the proportion of the most oxidative fibers helps in
counteracting diet-induced obesity [6], increasing type II/
glycolytic fibers promotes beneficial effects on obesity and
associated metabolic disorders [7].
In recent years, AMP-activated protein kinase (AMPK) has
emerged as a critical regulator of skeletal muscle oxidative function
[8]. The energy sensing capabilities of AMPK are attributed to its
ability to detect and react to fluctuations in the AMP/ATP ratio
that take place during rest and exercise. AMPK is a heterotrimer
comprised of catalytic a- and regulatory b- and c-subunits [9].
AMPK is activated by phosphorylation of threonine 172 (T172)
within the T-loop of the a-subunit catalyzed by either LKB1 or
Ca2+/calmodulin dependent protein kinase kinase (CaMKK) b
[10–12]. Recent studies have shown that the major mechanism for
activation of AMPK in response to ATP depletion is via binding of
AMP to the regulatory c subunit and protection against
dephosphorylation of T172 [13]. Once activated, AMPK restores
cellular energy balance by regulating transcription as well as
activity of enzymes implicated in the control of fatty acid and
glucose utilization. It has been accepted for long time that AMPK
acts on fatty acid transport into the mitochondria via phosphor-
ylation and inhibition of acetyl-CoA carboxylase (ACC) which
converts acetyl-CoA to malonyl-CoA, an inhibitor of carnitine
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palmitoyltransferase-1 (CPT-1) [14] thus leading to subsequent
oxidation of fatty acids. Interestingly, there is growing body of
evidence that AMPK and/or ACC phosphorylation does not
systematically correlate with increased fatty acid oxidation
suggesting the existence of additional kinases and/or signaling
pathways implicated in this process [15]. In addition, AMPK acts
on glucose utilization by increasing the expression of glut4 and its
translocation to the plasma membrane leading to increased
glucose uptake in skeletal muscle, independently of insulin [16],
[17]. This mode of action is consistent with recent evidence
indicating that AMPK plays a role in the therapeutic benefits of
exercise [14], [18] as well as metformin [19], [20] in the treatment
of type 2 diabetes and associated metabolic disorders.
Recent evidence indicates that Receptor-interacting protein 140
(RIP140) is a multi-functional coregulator with a central role in
metabolic tissues [21–25]. It binds and represses a number of
nuclear receptors including the peroxisome proliferator activated
receptors (PPARa, PPARb/d, and PPARc) [26], thyroid hormone
receptors (TRa, and TRb) [27] and estrogen-related receptors
(ERRa, and ERRb) [28] particularly important in regulating
metabolic gene expression in adipose tissue, muscle and liver [29].
The metabolic properties of skeletal muscle can be regulated by
nuclear receptors with coactivators playing a key role [6], [30–32].
Similarly, transcriptional repression by nuclear receptors is now
emerging as a key contributor to muscle physiology [33]. There is
substantial evidence to indicate that RIP140 functions as a
corepressor in skeletal muscle to control fiber type switching and
metabolism [25], [34], [35].
Previously, we studied the effect of RIP140 in skeletal muscle,
through loss or gain of function using RIP140-null and transgenic
mice [25]. The design of the study was based on the endogenous
level of RIP140 mRNAs, higher in glycolytic compared to
oxidative muscles, and led to the main conclusion that RIP140
acts as a transcriptional corepressor that inhibits oxidative
metabolism [25]. In addition to supporting this conclusion, the
data presented in this study show that absence of RIP140 reveals
an unexpected pathway regulating glucose uptake in the soleus.
Results
RIP140 participates in the glycolytic phenotype of the
EDL by inhibiting fatty acid utilization
Previously, we have shown that RIP140 mRNA levels are
higher in glycolytic muscles, EDL and gastrocnemius, compared to
oxidative ones, soleus and diaphragm [25]. While further
investigating RIP140 expression in the same tissues, we were
surprised to observe no significant difference in RIP140 protein
levels among tested skeletal muscles (Figure 1A, B). Therefore, as
there is no gradient of RIP140 protein expression in skeletal
muscles we were prompted to reassess RIP140 function as a
negative regulator of energy metabolism in both oxidative and
glycolytic muscles.
We analyzed the effect of modulating RIP140 levels on the rate
of b-oxidation in isolated EDL and soleus. Absence of RIP140
induced increased b-oxidation in the glycolytic-rich EDL to a level
similar to that observed in the oxidative-rich soleus (Figure 2A). In
WT muscles, b-oxidation was two- to three-fold lower in the EDL
compared to the soleus (Figure 2A). Analysis of mRNA levels of
key metabolic genes implicated in fatty acid handling showed that
FABP3, CD36, MCAD, CPT1b, CPT2, CIDEA and ACC2 were
increased in the absence of RIP140 in the EDL while unaffected in
the soleus, except for FABP3 (Figure 2B). Protein levels for RIP140
and FABP3, a key target implicated in fatty acid transport, were
analyzed and confirmed the changes observed at the mRNA level
(Figure 2C). In contrast, absence of RIP140 did not affect b-
oxidation in the soleus suggesting that RIP140 does not suppress
fatty acid utilization in this oxidative muscle (Figure 2A). To
further characterize the role of RIP140 in metabolic regulation, we
monitored the effect of exogenous expression of RIP140 in muscles
from a RIP140 transgenic mouse model. Exogenous expression of
RIP140 decreased the rate of b-oxidation in the soleus to a level
similar to that observed in the EDL (Figure 3A). No change in b-
oxidation rate is observed in the EDL, indicating that maximal
repression of fatty acid utilization is exerted in this muscle. In both
muscles, exogenous RIP140 caused reduced expression of genes/
proteins implicated in fatty acid transport (Figure 3B–C). These
data show that RIP140 acts as a transcriptional corepressor that
maintains the glycolytic properties of the EDL by inhibiting fatty
acid utilization.
RIP140 has been shown to act as a transcriptional corepressor
for metabolic nuclear receptors ERRs, PPARs as well as for NRF1
and TFam, two transcription factors controlling mitochondrial
function and biogenesis. Analysis of mRNA expression in the
soleus and EDL showed that overexpression of RIP140 reduced
levels of ERRa, PPARa and TFam while absence of RIP140
upregulated PPARa mRNAs (Figure 4A–C) suggesting that
RIP140 regulates the expression of these genes similarly in both
muscles. In parallel, absence of RIP140 did not affect the
expression of PPARb/d (Figure 4A, C) and NRF1 (Figure 4A)
in both muscles while overexpression of RIP140 inhibited NRF1
mRNAs only in the EDL (Figure 4B). Contrary to other targets,
SREBP1, implicated in fatty acid synthesis, is upregulated when
RIP140 is overexpressed in the soleus while absence of RIP140
inhibits its expression in the EDL (Figure 4A, B). This is in
agreement with RIP140 acting as a coactivator for LXR in
regulating the expression of SREBP1 in the liver [22]. In addition,
Figure 1. RIP140 protein level is the same in oxidative and glycolytic muscles. (A) Analysis of soleus (SOL), EDL, diaphragm (DIA), and
gastrocnemius (GAS) protein extracts by western-blot for RIP140 and actin expression. (B) Quantification of the western-blot for RIP140. Data are
expressed as mean 6 SEM.
doi:10.1371/journal.pone.0032520.g001
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the expression of the metabolic coactivator PGC-1b is downreg-
ulated by RIP140 overexpression in both muscles while upregu-
lated by the depletion of RIP140 only in the EDL (Figure 4A, B).
The difference observed in the level of NRF1, SREBP1 and PGC-
1b in the EDL and soleus suggests that RIP140 acts in a fiber type-
specific manner to regulate the expression of these genes. Thus,
RIP140 functions as a corepressor in both the EDL and soleus
regulating the expression of a number of transcription factors and
nuclear receptors but it may also function as a coactivator, for
example for SREBP1 gene, thereby acting as an important
regulator of metabolic gene expression.
Depletion of RIP140 increases GLUT4 trafficking and
basal glucose uptake in the soleus through activation of
AMPK
Mice devoid of RIP140 display enhanced glucose tolerance and
responsiveness to insulin compared to WT littermates [24]. To
define comprehensively the metabolic role of RIP140 in muscle,
we investigated changes in glucose disposal by skeletal muscles at
rest and analyzed the effect of RIP140 on glucose uptake.
Overexpression of RIP140 resulted in decreased 2-deoxyglucose
uptake in the EDL, with negligible change in the soleus
(Figure 5A). In parallel, expression analysis shows that the
insulin-independent glucose transporter, glut1, was not affected
(Figure 5B). Interestingly, the profile of glut4 mRNAs (lower in the
RIP140 transgenic EDL and unaffected in the soleus) correlates
with that of glucose uptake in the same muscles overexpressing
RIP140 (Figure 5A–B and Figure S1) suggesting that RIP140
controls glucose uptake through the regulation of glut4 expression.
Next, we investigated how depletion of RIP140 might affect
glucose transport in RIP140-null skeletal muscles. Glucose uptake
was increased in the isolated soleus of RIP140-null mice with no
change in the EDL (Figure 5C) suggesting that endogenous
RIP140 participates in the oxidative phenotype of the soleus by
inhibiting glucose uptake. In RIP140-null isolated muscle, in
contrast to RIP140 transgenic muscles, changes in glucose uptake
only partially rely upon changes in glucose transporter mRNAs
(Figure 5C–D). Thus, we hypothesized that GLUT4 sub-cellular
localization might be affected as it is known to be subject to
regulation. Increased GLUT4 immunoreactivity was detected as
increased granular staining observed in the sarcoplasma and
associated with the plasma membrane of myotubes in the soleus of
RIP140-null mice (Figure 5E) whereas glut4 mRNA and protein
expression was unaltered (Figure 5D, F). Together, these data
show that RIP140 controls glucose uptake through regulation of
glut4 expression and sub-cellular localization in skeletal muscle.
GLUT4 trafficking is controlled by two independent pathways
(i) insulin, predominantly via the PI3K/Akt signaling pathway and
(ii) AMPK. First, we investigated Akt activity (reflected by the
phospho-Akt to Akt ratio) in the soleus and EDL and found it was
unaffected by depletion as well as by exogenous expression of
RIP140 (Figure S2A–B). This is consistent with previous data
failing to show any alteration in Akt phosphorylation/activity in
RIP140-null adipocytes [24]. In contrast to the Akt finding,
absence of RIP140 led to increased AMPK activity as interpreted
by increased phospho-AMPK to AMPK (Figure 6A) and phospho-
ACC to ACC ratios (Figure 6B) in the soleus suggesting that
endogenous RIP140 inhibits AMPK phosphorylation and thus
activity. Consistent with this finding, exogenous RIP140 expres-
sion decreased AMPK and subsequent ACC phosphorylation in
the soleus (Figure 6A–B). Interestingly, expression of exogenous
RIP140 led to upregulation of total AMPK a-subunit proteins in
the soleus (Figure 6A). In the EDL, absence of RIP140 led to
Figure 2. Absence of RIP140 increases fatty acid utilization in the EDL. (A) b-oxidation rate, normalized to proteins, monitored in EDL and
soleus (SOL) isolated from RIP140-null (KO) and WT mice (n = 4). Data are expressed as mean 6 SEM. *p,0.05, WT vs KO; {{p,0.01, WT soleus vs WT
EDL. (B) Real-time RT-PCR analysis of genes implicated in fatty acid binding and transport in EDL and soleus (SOL) of RIP140-null (KO) and WT mice.
Data are comparable between histograms for the same gene and expressed as mean 6 SEM. *p,0.05, WT vs KO. (C) Analysis of RIP140, FABP3 and
actin expression in RIP140-null (KO) and WT EDL and soleus (SOL) by western blot.
doi:10.1371/journal.pone.0032520.g002
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increased AMPK phosphorylation (Figure S3) whereas in RIP140
transgenic mice, little change was observed in AMPK phosphor-
ylation and total a-subunit proteins in the same muscle (Figure S3).
We ruled out RIP140-dependent inhibition of LKB1 expression as
the mechanism affecting AMPK activity as LKB1 expression was
unaltered in either RIP140-null and transgenic muscles (data not
shown). This suggests that another mechanism is responsible for
the regulation of AMPK phosphorylation/activity by RIP140.
Absence of RIP140 leads to expression of UCP1 in the
soleus
The activity of AMPK is inhibited by elevated intracellular ATP
production. Paradoxically, in RIP140-null muscles, AMPK
activity is upregulated together with b-oxidation and glucose
uptake, processes known to produce ATP. Thus, we postulated
that a mechanism mimicking a defect in ATP production, i.e
mitochondrial uncoupling, could be responsible for AMPK
activation. Recently, we have shown that RIP140 acts as a
transcriptional corepressor for UCP1 and that depletion of
RIP140 in white adipose tissue leads to ectopic expression of
UCP1 [21], [24], [36]. Although UCP1 is a specific marker of
brown adipose tissue [37], we found increased UCP1 mRNA in
skeletal muscles of RIP140-null soleus and EDL compared to WT
(Figure 7A). When analyzed by western blot, UCP1 protein was
detectable in the soleus of RIP140-null mice but not the EDL
(Figure 7B). In addition, we checked for UCP1 proteins by
immunohistochemistry. In the soleus, a subset of RIP140-null
myofibers was stained positive for UCP1 when compared to the
negative control or WT (Figure 7C panels A, B, D and Figure S4).
The UCP1 staining of RIP140-null myofibers was much lower
than detected in brown adipose tissue, used as a positive control
(Figure 7C panels C, D). Analysis of MyHC profile showed that
fibers positive for UCP1 were also positive for MyHCIIa
(Figure 7C panels D, F). Expression of other mitochondrial
uncoupling proteins such as ANT1, ANT2, UCP2 and UCP3
were unaffected by the absence of RIP140 in the soleus (Figure
S5). In order to get functional insight about potential uncoupling,
we have tested the respiration capacities of RIP140-null myofibers
isolated from the soleus. Respiration of WT and RIP140-null
permeabilized myofibers, isolated from the soleus, was initiated
with pyruvate and uncoupled respiration was induced by addition
of palmitate with no difference observed (Figure 7D). Addition of
CAT (carboxyatractylate, a specific inhibitor of ANT proteins that
might be responsible for uncoupling respiration in our conditions)
slightly decreases WT myofibers respiration with no effect on
RIP140-null one (Figure 7D). However, in the presence of GDP (a
specific inhibitor of UCP1 function), we observed a decrease,
although not significant, of palmitate-induced respiration of
RIP140-null myofibers, but not of WT, suggesting that there
might be increased UCP1 uncoupling activity in RIP140-null
permeabilized myofibers (Figure 7D). Altogether these data show
that absence of RIP140 leads to a fiber type-dependent increase in
Figure 3. Exogenous expression of RIP140 inhibits fatty acid utilization in the soleus. (A) b-oxidation rate, normalized to proteins,
monitored in EDL (n = 8) and soleus (SOL) (n = 4) isolated from RIP140 transgenic (TG) and WT mice. Data are expressed as mean6 SEM. *p,0.05, WT
vs KO; {p,0.05, WT soleus vs WT EDL. (B) Real-time RT-PCR analysis of genes implicated in fatty acid binding and transport in EDL and soleus (SOL) of
RIP140 transgenic (TG) and WT mice. Data are comparable between histograms for the same gene and expressed as mean6 SEM. *p,0.05, WT vs TG.
???Data were published already in [25]. (C) Analysis of RIP140, FABP3 and actin expression in RIP140 transgenic (TG) and WT EDL and soleus (SOL) by
western blot.
doi:10.1371/journal.pone.0032520.g003
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UCP1 expression associated with potential increased uncoupling
activity.
RIP140 inhibits UCP1 promoter activity in C2C12 cells
Recently, we demonstrated that RIP140 regulates UCP1
expression through histone and DNA methylation in adipocytes
[36]. Although we detected hypomethylation of the UCP1
promoter in the soleus, there was no change in the methylation
status of the proximal promoter in RIP140-null compared to WT
soleus in bisulfite sequencing experiments (Figure S6). To
determine if UCP1 is regulated in muscle cells by PGC-1a and
RIP140 in the same way as in adipocytes, a UCP1 promoter
reporter construct was transfected into C2C12 cells together with
PPARa, PPARb/d or ERRa, well-known activators of UCP1
expression in adipocytes. When cells were treated with agonists for
PPARa or PPARb/d, WY14643 and GW501516 respectively,
UCP1 promoter activity was induced modestly (Figure S7A, B).
Cotransfection of PPARa or PPARb/d expressing vectors
increased further basal and ligand-induced promoter activity
(Figure S7A, B). In order to mimic an oxidative muscle
environment, RIP140 protein level was kept constant and cells
were transfected with PGC-1a. Addition of PGC-1a potentiated
UCP1 promoter activity in the presence of PPARa and PPARb/d
(Figure 8A, B) and increasing amount of RIP140 lead to a dose-
dependent inhibition of UCP1 promoter activity in the presence of
PPARa (Figure 8A). In the presence of PPARb/d, the minimal
dose of RIP140 (0.01:1) relative to PGC-1a inhibited the activity
of the promoter (Figure 8B). UCP1 promoter activity was
increased by transfection of ERRa and antagonized by the
addition of the inverse agonist XCT790 (Figure S7C and 8C).
Figure 4. Modulation of RIP140 alters the expression of metabolic nuclear receptors and transcription factors. (A) Real-time RT-PCR
analysis of metabolic nuclear receptors and transcription factors in soleus (SOL) and EDL of RIP140-null (KO) and WT mice. Data are comparable
between histograms for the same gene and expressed as mean 6 SEM. *p,0.05, WT vs KO. (B) Real-time RT-PCR analysis of metabolic nuclear
receptors and transcription factors in soleus (SOL) and EDL of RIP140 transgenic (TG) and WT mice. Data are comparable between histograms for the
same gene and expressed as mean 6 SEM. *p,0.05, WT vs TG. ???Data were published already in [25]. (C) Analysis of ERRa, PPARa, and PPARb/d
expression in RIP140-null (KO), transgenic (TG) and WT soleus (SOL) and EDL by western blot.
doi:10.1371/journal.pone.0032520.g004
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Figure 5. Depletion of RIP140 increases the presence of GLUT4 at the plasma membrane and basal glucose uptake in the soleus. (A)
Basal glucose uptake, normalized to proteins, monitored in EDL (n = 4) and soleus (SOL) (n = 8) isolated from RIP140 transgenic (TG) and WT mice.
Data are expressed as mean 6 SEM. *p,0.05, WT vs KO; {p,0.05, WT soleus vs WT EDL. (B) Real-time RT-PCR analysis of genes implicated in glucose
transport in EDL and soleus (SOL) of RIP140 transgenic (TG) and WT mice (n = 4). Data are expressed as mean 6 SEM, *p,0.05, WT vs TG. (C) Basal
glucose uptake, normalized to proteins, monitored in EDL and soleus (SOL) isolated from RIP140-null (KO) versus WT mice (n = 4–8). Data are
expressed as mean6 SEM, *p,0.05, WT vs KO; {p,0.05, WT EDL vs WT soleus. (D) Real-time RT-PCR analysis of genes implicated in glucose transport
RIP140 Regulates Glucose Uptake in the Soleus
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Addition of PGC-1a upregulated ERRa-induced promoter
activity and partially alleviated the downregulation observed in
the presence of XCT790 (Figure 8C). In the presence of ERRa,
the maximum dose of RIP140 (1:1) relative to PGC-1a inhibited
the activity of UCP1 promoter. Although the three nuclear
receptors are capable of regulating UCP1 expression, PPARb/d
transcriptional activity stimulated by PGC-1a seems to be the most
sensitive to the inhibition exerted by RIP140 in muscle cells.
In brown adipose tissue, UCP1 expression is induced by cold
through activation of the b-adrenergic signaling pathway resulting
in the activation of CREB and ATF2 transcription factors.
Treatment of the cells with forskolin, an activator of cAMP
production and subsequent activation of CREB, led to a two-fold
increase in UCP1 promoter activity (Figure S7D). When CREB or
ATF2 were expressed, UCP1 promoter activity was upregulated
by up to 13 fold, compared to three-fold with PPARb/d (Figure
S7B, D). Although addition of forskolin had no effect on CREB-
induced promoter activity, increased expression of PGC-1a
potentiated and RIP140 inhibited, in a dose-dependent manner,
the activity of UCP1 promoter in the presence of both CREB and
ATF2 transcription factors (Figure 8D). Altogether these data
show that expression of UCP1 in muscle cells is regulated by the
same factors as in adipocytes suggesting that cold might be capable
of inducing UCP1 expression in muscle cells and that RIP140 acts
as a transcriptional corepressor for all of them.
Discussion
In this study, we show that RIP140 inhibits glucose uptake in the
soleus and participates in the maintenance of its oxidative properties.
Importantly, we show that depletion of RIP140 unmasks a signaling
pathway upregulating insulin-independent glucose uptake in oxida-
tive muscle through increased expression of UCP1, activation of
AMPK, and, increased trafficking of GLUT4 (Figure 9).
The gene encoding RIP140 contains the full protein coding
sequence within a single exon, designated exon 5, but has multiple
promoters and 59 non-coding exons that are subject to tissue- and
cell-specific alternative splicing [38]. Expression analysis showed a
difference in RIP140 mRNAs between skeletal muscles, higher in
glycolytic muscles, such as the gastrocnemius and the EDL, and
lower in oxidative-rich muscles, like the soleus and diaphragm
[25]. Quantitative RT-PCR experiments were performed using a
set of primer specifically targeting exon 5 enabling the detection of
all RIP140 mRNA species present in skeletal muscles and
potentially subject to translation [25]. Because the difference
observed for RIP140 mRNAs between skeletal muscles does not
seem to be translated into proteins, this suggests that post-
transcriptional and/or post-translational modifications may ac-
count for this discrepancy. The existence of microRNAs targeting
RIP140, such as miR346 discovered in the brain, that increases
the stability of RIP140 proteins [39], might explain the
discrepancy observed between skeletal muscles. Interestingly, the
expression of such microRNAs should be subject to fiber type-
dependent regulation to satisfy the hypothesis. Alternatively, it has
been demonstrated that RIP140 is subject to ubiquitination and
degradation via the ubiquitin/proteasome pathway [40] enabling
the control of RIP140 activity via the regulation of its half-life.
Fiber type-dependent ubiquitination/degradation has been impli-
cated in the regulation of other transcriptional corepressors, class
II HDACs, in skeletal muscles [41] and the effect on RIP140 has
yet to be tested. Although total RIP140 protein levels are similar in
type I- and type II-containing muscles, there are still questions
concerning the distribution of RIP140 proteins among fibers and
this is dependent on the availability of antibodies of high quality
in EDL and soleus (SOL) of RIP140-null (KO) and WT mice (n = 4). Data are expressed as mean 6 SEM, ***p,0.001, WT vs KO. (E)
Immunohistochemistry for GLUT4 on RIP140-null (KO) and WT soleus. Lower panels show increased magnification of upper panels (scale
bar = 100 mm). (F) Analysis of GLUT4 and tubulin expression in RIP140-null (KO) and WT soleus (SOL) by western blot.
doi:10.1371/journal.pone.0032520.g005
Figure 6. RIP140 modulates AMPK activity. (A) Analysis of phospho-aAMPK, total a and b AMPK expression on RIP140-null (KO), transgenic (TG)
and WT soleus (SOL) by western-blot. Quantification of phospho-AMPK to AMPK ratio for western-blot expressed as mean 6 SEM. (B) Analysis of
phospho-ACC and total ACC expression on RIP140-null (KO), transgenic (TG) and WT soleus (SOL) by western-blot. Quantification of phospho-ACC to
ACC ratio for western-blot expressed as mean 6 SEM. Data are presented with WT set to one.
doi:10.1371/journal.pone.0032520.g006
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Figure 7. Absence of RIP140 leads to fiber-type specific expression of UCP1 in the soleus. (A) Real-time RT-PCR analysis of UCP1 mRNA
level in EDL and soleus (SOL) of RIP140-null (KO) versus WT mice (n = 5). Data are expressed as mean6 SEM, *p,0.05, WT vs KO; #p,0.05, WT EDL vs
WT soleus. (B) Analysis of UCP1 expression by western-blot on 50 mg of proteins extracted from UCP1-null soleus (ucp1 KO), RIP140-null (KO) and WT
soleus, RIP140-null (KO) and WT EDL, except for brown adipose tissue (BAT, 1 mg). (C) Immunohistochemistry for UCP1 on WT and RIP140-null (KO)
soleus (panels B and D, respectively) with brown adipose tissue as positive control for UCP1 (BAT, panel C) and WT soleus incubated with primary
antibody omitted as negative control (Neg, panel A). Immunohistochemistry for MyHCIb (panel E) and MyHCIIa (panel F) on RIP140-null soleus.
*Asterisks represent fibers positive for both UCP1 and MyHCIIa (scale bar = 100 mm). (D) Respiration of skinned myofibers isolated from RIP140-null
(KO) and WT soleus was monitored after successive addition of pyruvate/malate (pyr/mal), palmitate (palm), carboxyatractylate (cat), gdp and fccp.
Data are expressed as fold induction 6 SEM, with respiration after addition of pyruvate/malate set to one for both RIP140-null and WT conditions.
doi:10.1371/journal.pone.0032520.g007
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for immunohistochemistry/immunofluorescence experiments. Al-
together, these are pertinent questions that are under investigation.
Most of the genes affected by the absence of RIP140 are
upregulated which is consistent with RIP140 acting mainly as a
transcriptional corepressor. In addition, most of the genes
repressed by RIP140 are activated by PGC-1a, the transcriptional
coactivator being expressed at higher level in oxidative muscles
compared to glycolytic ones [32]. Recently, we have shown that
RIP140 interacts directly with PGC-1a and suppresses its activity
[42] strengthening the mutually antagonistic functions of the two
coregulators. This raises the possibility that direct antagonism of
PGC-1a by RIP140 may provide the basis of a fiber type-
dependent mechanism for tight regulation of metabolic gene
expression. In the soleus, removing the corepressor RIP140 does
not alter the expression of target genes suggesting that the balance
of metabolic cofactors is in favor of the pro-oxidative ones such as
PGC-1a. On the other hand, metabolic gene expression and
subsequent b-oxidation is downregulated in RIP140 transgenic
soleus suggesting that increased expression of RIP140 enables the
titration of PGC-1a, or other pro-oxidative factors, sequestering
them away from target gene promoters. In the EDL, removal of
RIP140 induces the upregulation of metabolic genes and
subsequent b-oxidation without altering the uptake of glucose.
This is in line with endogenous RIP140 acting at the transcrip-
tional level to maintain the glycolytic properties of the EDL
through inhibition of b-oxidation. However, increasing RIP140
level leads to the decrease of genes involved in the regulation of
fatty acid uptake and transport in the transgenic EDL, without
Figure 8. UCP1 promoter activity is induced by PGC-1a and inhibited by RIP140 in C2C12. Cells were transfected with UCP1(4 kb)-
luciferase reporter and vectors expressing (A) PPARa, (B) PPARb/d, (C) ERRa, (D) CREB or ATF2 with or without a vector expressing PGC-1a, and
increasing amount of RIP140 (0,01:1; 0,1:1 and 1:1 relative to PGC-1a), and treated with (A) 100 mM WY14643 (WY), (B) 10 mM GW501516 (GW), (C)
10 mM XCT790 (XC), (D) 10 mM Forskolin (Fo) or vehicle (-) as indicated. Data are expressed as mean 6 SEM.
doi:10.1371/journal.pone.0032520.g008
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affecting the rate of b-oxidation. This suggests that other
regulators are rate-limiting and might be acting to maintain a
basal state of b-oxidation in this glycolytic muscle that is resistant
to the action of increased RIP140. This threshold is a brake that
might rely on the control of enzymatic activities directly involved in
fatty acid utilization. This is compatible with the existence of a
balance between RIP140 and PGC-1a that ensures the fine tuning
of skeletal muscle metabolism in response to environmental
changes. Interestingly, nuclear receptors as well as transcription
factors implicated in the regulation of energy metabolism are
differentially affected by the action of RIP140. The transcriptional
activity of PPARa, ATF2 and CREB, in the context of UCP1
promoter, is inhibited in a dose-dependent manner by RIP140
confirming that the balance between RIP140 and PGC-1a relies on
the direct antagonism between the two coregulators. Regarding
PPARb/d, its activity is more sensitive to the action of RIP140 as far
less RIP140 is necessary to block the upregulation induced by PGC-
1a. Thus, a low level of RIP140 is capable of blocking the action of
PGC-1a, depending on the transcriptional context, and it adds a
supplementary level of complexity to the balance between RIP140
and PGC-1a coregulator activity. In addition, we cannot exclude
that PGC-1a activity is indirectly modulated by RIP140 through
AMPK as shown previously [43]. Expression of PGC-1a itself is not
affected by modulation of RIP140 protein level but we found that
expression of PGC-1b is upregulated in RIP140-null EDL. This is
consistent with the ability of PGC-1b to drive the expression of
MyHCIIx fibers [44] and might contribute to the modulation of
contractile properties observed in RIP140-null mice [25].
Ablation of RIP140 expression leads to a mild fiber type switch
in favor of MyHCIIx and MyHCIIa [25]. Interestingly, data from
Figure 9. Schematic representation of the different steps leading to glucose uptake due to depletion of RIP140 in oxidative muscle.
Absence of RIP140 leads to expression of UCP1 and mitochondrial uncoupling. Then, alteration of the AMP to ATP ratio in favor of elevated AMP
activates AMPK which in turn stimulates GLUT4 translocation to the plasma membrane enabling the entry of glucose from blood circulation.
doi:10.1371/journal.pone.0032520.g009
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immunohistochemistry experiments show that depletion of
RIP140 leads to specific expression of UCP1 in MyHCIIa fibers
ruling out the contamination of muscle samples with brown
adipocytes. In addition, the difference in UCP1 mRNAs between
the RIP140-null EDL and soleus is consistent with the relative
proportion of their MyHCIIa myofiber content, 20% and 53%
respectively [25] and this increase in oxidative fibers is consistent
with improvement of insulin sensitivity and metabolic parameters
in RIP140-null mice. UCP1 has been shown to be almost
exclusively expressed in the brown fat conferring to this tissue its
specific function in non-shivering thermogenesis [37], [45].
Although controversial, there is growing evidence that UCP1 is
expressed in other tissues such as the thymus [46], the white
adipose tissue and skeletal muscles [21], [23], [47], [48]. Mice
devoid of RIP140 have increased oxygen consumption and
respiratory exchange ratio compared to WT littermates [25]
suggesting they utilize fatty acids as the main source of energy.
This is confirmed by elevated b-oxidation rate found in both
adipocytes [21] and the EDL of RIP140-null mice (herein). In
particular, we have shown that RIP140 acts simultaneously on
fatty acid transport and mitochondria number and activity [25],
[35] to ultimately alter b-oxidation rate in skeletal and cardiac
muscles. Absence of RIP140 leads to ectopic expression of UCP1
in the white adipose tissue [23] suggesting that mitochondrial
uncoupling might be implicated as well. The induction of UCP1
and the conversion of white adipocytes to a brown fat phenotype
have also been achieved by the ectopic expression of PGC-1a [32].
Recently, we have shown that RIP140 regulates UCP1 expression
through histone and DNA methylation in adipocytes [36].
However, our bisulfite sequencing experiments failed to show
any changes in the methylation status of UCP1 promoter in
RIP140-null soleus compared to WT. Surprisingly, we found that
UCP1 promoter is hypomethylated suggesting that the local
chromatin displays a permissive state compatible with active
regulation of UCP1 expression in skeletal muscles. This is
consistent with our data demonstrating that PGC-1a, PPARa,
PPARb/d and ERRa are capable of regulating UCP1 promoter
activity in muscle cells in the same way as in adipocytes. In
addition, expression of UCP1 and its potential regulation by cold
through activation of ATF2 and CREB transcription factors, in
skeletal muscle is relevant in the light of recent data suggesting that
skeletal muscle shares the same lineage as brown adipose tissue
[49], [50].
The control of glucose uptake into skeletal muscle by regulation
of the expression and trafficking of specific transporters is essential
for the maintenance of euglycaemia. In this study, we show that
absence of RIP140 leads to increased GLUT4 trafficking and
glucose uptake in the soleus independently of insulin. Although
GLUT4 mediates insulin-dependent glucose transport, this is
consistent with data from GLUT4-muscle specific knockout mice
showing that GLUT4 participates in the basal glucose uptake in
the EDL [51]. The mechanism by which GLUT4 trafficking is
increased relies on activation of AMPK due to ectopic expression
of UCP1 and increased, although not significant, energy
dissipation. These data are consistent with previous studies
demonstrating that ectopic expression of UCP1 in skeletal muscle
leads to upregulation of AMPK activity and increased glucose
uptake preventing diet-induced obesity and insulin resistance [52],
[53]. Metformin, a drug widely used to treat insulin resistance in
obese and type 2 diabetic patients, improves glucose disposal by
skeletal muscle and affects hepatic glucose production [54].
Metformin is thought to act mainly by enhancing AMPK activity
through changes in the AMP to ATP ratio [19], [20]. AMPK plays
an important role in the beneficial effects of metformin and is part
of the mechanism by which contraction-induced glucose uptake is
achieved. In adipocytes, it was recently demonstrated that
cytoplasmic RIP140 modulates GLUT4 trafficking through a
mechanism that is distinct from transcriptional regulation [55].
This is the consequence of RIP140 interacting with AS160 and
impeding its inactivation by Akt. High fat diet stimulates RIP140
nuclear export in white adipose tissue and blocks transcriptional
regulating properties of RIP140 [56]. In skeletal muscle, RIP140 is
preferentially localized in the nucleus (data not shown) but we
cannot rule out the possibility that RIP140 may also be localized in
the cytoplasm or that high fat diet affects its localization. This
provides an additional mechanism that might be implicated in the
regulation of glucose uptake in the EDL and should be
investigated further.
In RIP140 transgenic mice, AMPK activity is inhibited in the
soleus. This is accompanied by decreased b-oxidation that reflects
alteration in expression of genes implicated in fatty acid binding
and transport, with no change in the uptake of glucose. This
suggests that there is a minimal threshold of glucose uptake that is
maintained in the soleus and, similar to the state of b-oxidation in
the EDL, it is refractory to further inhibition by increased RIP140
and subsequent inhibition of AMPK phosphorylation/activation.
Because UCP1 is normally undetectable in skeletal muscles, the
effect of exogenous RIP140 on AMPK cannot be explained by
alteration in mitochondrial uncoupling. AMPK exists in the cell as
heterotrimeric complexes with different combinations of isoforms
displaying selective affinity for its allosteric activator, AMP [57–
59]. Interestingly, we detect increased expression of subunits a
(herein) and c3 [25] in RIP140 transgenic soleus suggesting that
the decrease in AMPK activity could be due to the formation of
specific complexes with lower activity. In addition, RIP140 seems
to act as a transcriptional coactivator for these genes as found in a
number of other cell systems [42], [60], [61] and this should be
investigated further.
In conclusion, this study shows that depletion of RIP140
improves the metabolic parameters of both glycolytic and
oxidative muscles which participates in the overall phenotype of
RIP140-null mice and suggest that RIP140 might be a potential
therapeutic target in the treatment of insulin resistance in obese
and type 2 diabetic patients.
Methods
Ethics statement
All animal studies were carried out according to UK Home
Office guidelines.
Animals
The generation of RIP140-null and RIP140 transgenic mice has
been described previously [22], [35].
Expression analysis
The expression of target genes was determined using SYBR
green reagent and gene-specific primers on the opticon 2 PCR
machine (MJ Research). Expression levels were normalized to
ribosomal coding gene RPL7.
Western-blot analysis
Muscle tissues were homogenized in buffer containing 50 mM
HEPES (pH 7.6), 150 mM NaCl, 5 mM EDTA, 1% NP40 with a
cocktail of phosphatase and protease inhibitors (SIGMA). Protein
concentration was determined by using the Bradford method (Bio-
Rad). Samples were resuspended in Laemmli buffer and proteins
separated on SDS-PAGE. Proteins were transferred to PVDF
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membranes (GE healthcare) and subjected to western blot analysis.
After incubation with primary antibodies, membranes were
incubated with secondary antibodies linked to horseradish
peroxidase (Dako). Quantification was made using NIH Image J
software. Primary antibodies used in this study were from Santa-
Cruz against PPARa (sc-9000), FABP3 (sc-58274) and GLUT4
(sc-7938); from Cell signaling against Akt (9272), phospho-Akt
(9276), AMPK (2532), phospho-AMPK (2531), ACC (3662),
phospho-ACC (3661); from SIGMA against UCP1 (U6382) and
PPARb/d (SAB2500812); from Novus Biologicals against ERRa
(NLS5402); from Abcam against actin (ab8226) and mouse
monoclonal anti-RIP140 (6D7) was made in house.
b-oxidation
Isolated muscles were pre-incubated for 30 min in Krebs-
Henseleit bicarbonate buffer (KRH: 25 mM NaHCO3, 118 mM
NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM NaH2PO4 and
1.2 mM CaCl2) with 20 mg/ml free-fatty acid BSA, 5 mM
glucose. The muscles were then transferred to KRH buffer
containing 20 mg/ml free-fatty acid BSA+0.3 mM L-Carnitine
and 12 mM 3[H]-palmitic acid (3 mCi/well) and incubated for
2 hours. The media was transferred to tubes containing one tenth
volume of TCA 50%. After centrifugation, the supernatant was
transferred to fresh tubes containing half volume of chloroform:-
methanol (2:1). After centrifugation, the aqueous phase was then
transferred to scintillation vials and the 3H2O production was then
measured with a scintillation counter. Then, muscles were
incubated with 0.1% SDS for 2 hours at 50uC and the extract
was assayed for protein concentration to normalize.
Glucose uptake
Isolated muscles were glucose starved by pre-incubating for
2 hours in KRH buffer. The muscles were then transferred to
KRH buffer containing 20 mg/ml free-fatty acid BSA+3H-2-
deoxyglucose (2 mCi/well) with 5 mM non-radioactive 2-deox-
yglucose for 5 min. The muscles were rapidly washed 3 times with
ice-cold KRH buffer to stop the reaction. Then the muscles were
transferred to eppendorf tubes with 0.1% SDS and incubated for
2 hours at 50uC. The extract was counted for radioactivity and
assayed for protein concentration to normalize.
Immunohistochemistry
Immunostaining was performed essentially as described previ-
ously [25] using primary antibodies from Santa-Cruz against
GLUT4 (sc-7938), UCP1 (sc-6528) and mouse monoclonals
against MyHCIIa (SC-71) and MyHCIb (BAF8). Monoclonals
for MyHC were a gift from Dr A. Rowlerson.
Promoter assays
C2C12 cells (purchased from ATCC) were transfected by using
lipofectamine 2000 (Invitrogen) with UCP1 (4 kb)-luciferase
reporter [21] together with vectors expressing RXR, PPARa,
PPARb/d, CREB (gift of Dr D.M. Stocco), ERRa, ATF2 (gift of
Dr M. Sabbah), RIP140 and PGC-1a as indicated. After overnight
incubation, cells were treated with 100 mM WY14643, 10 mM
GW501516, 10 mM XCT790, 10 mM Forskolin (Calbiochem) or
vehicle as indicated and harvested 24 h later for the determination
of luciferase and GFP (used to correct for differences in
transfection efficiencies) activities.
Preparation of skinned myofibers
Muscles isolated from mice were incubated in cooled relaxing
solution A containing 2.77 mM CaK2EGTA, 7.23 mMK2EGTA,
6.56 mM MgCl2, 0.5 mM DTT, 50 mM K-MES, 20 mM
Imidazole, 20 mM Taurine, 5.3 mM Na2ATP, 15 mM Phospho-
creatine (pH 7.1). The myofibers were separated out and
transferred into cooled solution A containing 50 mg/mL of
saponin. After, incubation at mild stirring for 30 min for complete
solubilisation of the sarcolemma, the skinned myofibers were
washed three times 10 min in solution B containing 2.77 mM
CaK2EGTA, 7.23 mM K2EGTA, 1.38 mM MgCl2, 0.5 mM
DTT, 100 mM K-MES, 20 mM Imidazole, 20 mM Taurine,
3 mM K2HPO4 (pH 7.1).
Mitochondrial oxygen consumption
Respiration of skinned myofibers was measured using a Clark
type electrode sensitive to oxygen in solution B containing
respiratory substrates and 2 mg/ml BSA. Skinned myofibers from
WT and RIP140-null soleus were energized with 5 mM pyruvate/
2 mM malate then 135 mM of palmitate was added to activate
uncoupling. UCP1-dependent uncoupling was determined in the
presence of 5 mM CAT and 0.5 mM GDP. Then 5 mM FCCP
was added to the chamber to test maximal capacity of
mitochondria preparation.
Statistical analysis
All data were analyzed by Student’s t-test. Significance level was
preset to p,0.5. Data are presented as mean 6 SEM across
experiments.
Supporting Information
Figure S1 Expression of GLUT4 is decreased in the
RIP140 transgenic EDL. Analysis of GLUT4 and tubulin
expression in RIP140 transgenic (TG) andWTEDL by western blot.
(TIF)
Figure S2 RIP140 does not alter Akt activity. (A) Analysis
of phospho-Akt and total Akt expression on RIP140-null (KO),
transgenic (TG) and WT soleus (SOL) and EDL by western-blot.
(B) Quantification of phospho-Akt to Akt ratio for western-blot
expressed as mean 6 SEM.
(TIF)
Figure S3 RIP140 does not alter AMPK activity in the
EDL. Analysis of phospho- aAMPK, total a and b AMPK
expression on RIP140-null (KO), transgenic (TG) and WT EDL
by western-blot. Quantification of phospho-AMPK to AMPK
ratio for western-blot expressed as mean 6 SEM.
(TIF)
Figure S4 Specificity of UCP1 antibody tested for
immunochemistry. Immunohistochemistry for UCP1 on
WT, RIP140-null (KO) and UCP1-null (KO) soleus. Sections
incubated with primary antibody omitted are displayed as negative
control (Neg).
(TIF)
Figure S5 Depletion of RIP140 does not alter the
expression of other mitochondrial uncoupling proteins
in the soleus. Real-time RT-PCR analysis of Ant1, Ant2,
UCP2, and UCP3 in the soleus (SOL) of RIP140-null (KO) and
WT mice. Data are expressed as mean 6 SEM.
(TIF)
Figure S6 UCP1 proximal promoter is hypomethylated
in the soleus. Bisulfite sequencing experiments were performed
on muscles isolated from the soleus (SOL) of RIP140-null (KO)
and WT mice. (n = 12–15).
(TIF)
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Figure S7 UCP1 promoter activity is inducible in
C2C12. Cells were transfected with UCP1(4 kb)-luciferase
reporter and vectors expressing (A) PPARa, (B) PPARb/d, (C)
ERRa, (D) CREB or ATF2, and treated with (A) 100 mM
WY14643 (WY), (B) 10 mM GW501516 (GW), (C) 10 mM
XCT790 (XC), (D) 10 mM Forskolin (Fo) or vehicle (-) as
indicated. Data are expressed as mean 6 SEM, *p,0.05 vs
vehicle.
(TIF)
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